Drug for Nervous-System Tumor Treatment Syracuse NY

In people with NF2, benign tumors develop throughout the nervous system. The most common tumor is a vestibular schwannoma, which grows on the nerve connecting the ear to the brain.

Nabila Adham Elbadawi, MD
(315) 474-4475
815 James St
Syracuse, NY
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Female
Education
Medical School: Kasr El Aini Fac Med Cairo Univ, Cairo (915-02 After 1/1971)
Graduation Year: 1960

Data Provided by:
Lawrence Carl Panasci, MD
750 E Adams St
Syracuse, NY
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Georgetown Univ Sch Of Med, Washington Dc 20007
Graduation Year: 1972

Data Provided by:
Ajeet Gajra
(315) 464-8200
750 E Adams St
Syracuse, NY
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Shirish Anant Mahajan, MD
750 E Adams St
Syracuse, NY
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Jawaharlal Inst Of Post-Grad Med Educ, Madras Univ, Pondicherry
Graduation Year: 1993

Data Provided by:
Chirag Mahesh Shah, MD
(315) 464-5540
750 E Adams St
Syracuse, NY
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Mp Shah Med Coll, Saurashtra Univ, Jamnagar, Gujarat, India
Graduation Year: 1992

Data Provided by:
Abdul Kader Souid
(315) 464-5294
750 E Adams St
Syracuse, NY
Specialty
Pediatric Hematology-Oncology

Data Provided by:
Sara Jo Grethlein, MD
(315) 464-8200
750 E Adams St
Syracuse, NY
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Mary J Cunningham, MD
(315) 470-5739
3rd Floor West Tower
Syracuse, NY
Specialties
Oncology (Cancer), Gynecological Oncology, Obstetrics And Gynecology
Gender
Female
Languages
Other
Education
Medical School: Northwestern Univ Med Sch, Chicago Il 60611
Graduation Year: 1984
Hospital
Hospital: Crouse Hosp, Syracuse, Ny; Suny Health Science Center, Syracuse, Ny
Group Practice: University Ob/Gyn Assoc

Data Provided by:
Angelie D Roman, MD
(315) 472-4584
2200 E Genesee St
Syracuse, NY
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: American Univ Of The Caribbean, Sch Of Med, Plymouth, Montserrat
Graduation Year: 1992
Hospital
Hospital: St Josephs Hospital Health Cen, Syracuse, Ny; Crouse Hosp, Syracuse, Ny
Group Practice: Syracuse Hematology Oncology P; Syracuse Hematology Oncology Pc

Data Provided by:
Chung-Taik Chung
(315) 464-5276
750 E Adams St
Syracuse, NY
Specialty
Radiation Oncology

Data Provided by:
Data Provided by:

Drug for Nervous-System Tumor Treatment

Provided By:

U.S. researchers report the first successful drug treatment of tumors in patients with neurofibromatosis type 2 (NF2).

In people with NF2, benign tumors develop throughout the nervous system. The most common tumor is a vestibular schwannoma, which grows on the nerve connecting the ear to the brain. This type of tumor, also called acoustic neuroma, causes hearing loss and can press on the brain stem, leading to serious neurologic symptoms and the risk of death.

Currently, these tumors are treated with surgery or radiation. This study found that treatment with the angiogenesis inhibitor bevacizumab (Avastin) shrank vestibular schwannomas, improved hearing and eased other symptoms in NF2 patients.

Bevacizumab is an anti-cancer drug designed to reduce blood flow to tumors in order to shrink them. But the drug wasn't used on acoustic neuromas because it was believed that they didn't stimulate formation of new blood vessels, as malignant tumors do.

But researchers at Massachusetts General Hospital in Boston analyzed tissue samples of NF2-related vestibular schwannomas and found evidence of excess blood vessel development. They then decided to test bevacizumab in 10 NF2 patients with vestibular schwannomas.

Tumor shrinkage occurred in nine patients, six of whom had a 20 percent or greater reduction in tumor size. The tumor shrinkage lasted between 11 and 16 months. Of the seven patients who had started to lose their hearing before treatment, four had some hearing restored. This improvement also lasted for up to 16 months.

"This kind of treatment response is unprecedented," lead author Dr. Scott Plotkin of the Pappas Center for Neuro-Oncology in the MGH Cancer Center, said in a news release. "Our study is the first to provide evidence that a drug can shrink vestibular schwannomas…and the first to show that patients' hearing can be improved."

The study will appear online in advance of publication in the July 23 issue of the New England Journal of Medicine.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about neurofibromatosis.

SOURCE: Massachusetts General Hospital, news release, July 8, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com